LENSAR, Inc. (LNSR)
Nasdaq · Healthcare · Medical Devices
$6.67−1.19%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $82.0M
- P/E (trailing)
- 37.1
- 52-week range
- $4.95 – $12.94
- 52-week change
- −44.03%
- EPS (trailing)
- $0.18
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $58.4M (+9.24%)
- Net income
- −$34.3M
- Operating margin
- −42.1%
- Diluted EPS
- −$2.87
- Free cash flow
- −$14.9M
From the company’s annual report on SEC EDGAR.
About LENSAR, Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Headquarters: Orlando, United States · 150 employees · lensar.com